Anavex Life Sciences Corp (AVXL)

[sokol]

Costs per patient for a phase III clinical trial. See this:

http://www.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-sponsored-clinical-trials-impact-on-state-economies.pdf

Page 11 shows Estimated Average Per-Patient Clinical Trial Costs, by Phase, 2013. It provides a figure of $42,000.00 per patient for a phase III clinical trial.

Assuming the above is more accurate than some poster throwing out figures without citing any basis or making some generalized statement that the AVXL 2-73 clinical trial cannot be done for $50,000,000, I believe this phase III trial can be done for less than $50,000,000.

Granted, costs vary per site and costs may increase from year to year, but even with a 100% increase for the per patient figure give above is $84,000.00 per patient X 300 patients = $25,200,000.

Traditional clinical trials include 1,000 - 5,000 or more patients. Anavex has designed its trials according to newer FDA guidelines to cost less as many long term posters here know.